How Effective Is CC-92480 Monotherapy or in Combination in RRMM?

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Addressing the Unmet Needs of Current Immunomodulatory Therapy in Multiple Myeloma

How Effective Is CC-92480 Monotherapy or in Combination in RRMM?

Minute CME/CE™
ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    With the introduction of both immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide, and the use of these in combination with drugs from other classes, IMiDs have made a dramatic progress in the treatment of multiple myeloma (MM). However, despite improvement in outcomes, patients with MM ultimately relapse and must undergo further treatment. Early studies show that Cereblon E3 Ligase Modulators (CELMoDs®) iberdomide and CC-92480 show similar trends in activity in patients refractory to IMiDs. This new next generation of IMIDs have shown enhanced tumoricidal and immune-stimulatory effects compared with first-generation IMiDs and have the potential to replace the current standard of care in both frontline and RRMM. This program covers the benefits as well as current challenges with the use of first-generation IMiDs while exploring the MOA, clinical, and safety activity to date of selective CELMoD® therapy in MM.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including hematologists/oncologists, nurses, pharmacists, as well as other clinicians involved in the management of patients with multiple myeloma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe the mechanism of action and unique characteristics of CELMoD® therapies that differentiate them from currently approved, first-generation IMiDs
    2. Evaluate efficacy data of first-generation IMiDs and CELMoD®-based therapies and the ability to use these agents in combination with current backbone therapy in multiple myeloma
    3. Compare the available data on the safety and tolerability of the CELMoD®-based therapies to current immunomodulatory agents in multiple myeloma
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty has reported relationships with ineligible companies:

    Sagar Lonial, MD, FACP, faculty for this educational event, is on contracted research for Janssen, BMS, and Takeda; receives consulting fees from Takeda, BMS, Janssen, GSK, AbbVie and Celgene; is on the board of directors and owns stock for TG Therapeutics.

    Maria V. Mateos, MD, PhD, faculty for this educational event, receives consulting fees from Janssen, BMS-Celgene, Takeda, Amgen, GSK, AbbVie, Pfizer, Regeneron, Roche, Sanofi, and Oncopeptides. 

    Krina Patel, MD, MSc, faculty for this educational event, is on contracted research for Nektar, Allogene; receives consulting fees from Janssen, Celgene/BMS, Merck, Pfizer, Caribou Biosciences, Legend, Cellectis, Karyopharm, and Oncopeptides.

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 8/30/2022 through 8/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 May 2023